Almirall, S.A. (BME: ALM)
Health Care · Pharmaceuticals · ES
€10.08
+0.20% today · -15.4% 1Y
Almirall, S.A. (BME: ALM) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $2.46B and employs 2,097 people.
Over the last twelve months the share price has lost 15.4%, trading between 10.02 and 13.98.
Tweenvest scores Almirall, S.A. across four factors: quality 76/100, value 71/100, growth 54/100, dividend 30/100. Its strongest factor is quality.
ALM price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.46B
- Revenue (TTM)
- $1.32B
- P/E
- 36.48
- EPS
- 0.28
- Dividend yield
- 1.86%
- Beta (5Y)
- 0.14
- 52-week high
- €13.98
- 52-week low
- €10.02
- Avg volume (3M)
- —
- Shares outstanding
- 217.78M
- Employees
- 2,097
- Next earnings
- —
About Almirall, S.A.
Almirall, S.A. is a biopharmaceutical firm dedicated to the discovery, development, production, and commercialization of treatments primarily focused on skin health. Operating globally, with a significant presence in Europe and the United States, its product line targets various dermatological ailments such as actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, and acne, alongside rare skin conditions. Beyond its core dermatology focus, the company also offers solutions for cardiovascular, musculoskeletal, respiratory, and nervous system disorders, as well as products for digestive health, anti-infectives for systemic use, genitourinary conditions and sex hormones, immunostimulants, and systemic hormonal preparations. Its extensive portfolio includes a range of well-known medications, such as Ilumetri, Solaraze, Skilarence, and Klisyri, among others. Almirall fosters strategic partnerships with numerous entities to advance its pipeline, including research institutions like the University of Dundee and commercial partners such as Eli Lilly and Company. Founded in Barcelona, Spain, in 1943, the company adopted its current name, Almirall, S.A., in May 2009, having previously been known as Laboratorios Almirall, S.A.
- ISIN
- ES0157097017
- Founded
- 1943
- Listed since
- Jun 20, 2007
- Exchange
- Bolsas y Mercados Espanoles
- Currency
- EUR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| MBX Biosciences, Inc.NasdaqGS: MBX | $2.56B | $53.24 | -9.01% |
| China Resources Double-Crane Pharmaceutical Co.,Ltd.SHSE: 600062 | $2.53B | CN¥16.44 | +1.23% |
| Supernus Pharmaceuticals, Inc.NasdaqGM: SUPN | $2.48B | $42.67 | +0.68% |
| Curaleaf Holdings, Inc.TSX: CURA | $2.47B | CA$13.31 | -6.33% |
| Liquidia CorporationNasdaqCM: LQDA | $2.45B | $27.38 | -2.28% |
| Aether Industries LimitedNSEI: AETHER | $2.40B | Rs1,748.10 | +4.68% |
| Jamjoom Pharmaceuticals Factory CompanySASE: 4015 | $2.39B | SR128.00 | +0.95% |
| Harmony Biosciences Holdings, Inc.NasdaqGM: HRMY | $2.35B | $40.28 | +1.72% |
Figures last refreshed Oct 11, 2026.